Royalty Report: Drugs, Supplements, Healthcare – Collection: 173732

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Supplements
  • Healthcare
  • Nutraceutical
  • Nutrition
  • Personal Care
  • Diet System
  • Drug Discovery
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 173732

License Grant
University and Licensee wish to amend the License Agreement.  This amendment modifies terms of the agreement including the royalty.
License Property
The agreement includes Products which are Pharmaceuticals (Rx), Over-The-Counter (OTC), and Dietary Supplement Health and Education Act (DSHEA) extracts or compounds.

Unlike the traditional drug development process of identifying and synthesizing single bioactive molecules from plant sources, the Company's core technologies were developed based on empirical data that suggests that the health benefits and safe usage of certain plant-derived therapeutics might be the result of the natural combination of multiple molecules found in the plant extract and that single molecules, in isolation, may not replicate the natural plants' effectiveness. The PharmaPrint Process technology enables the Company to identify and quantify the bioactives within plant sources that are believed to provide therapeutic benefits and produce dietary supplements and pharmaceuticals having consistent batch-to-batch quantities and ratios of these bioactives.

Field of Use
This agreement is for the pharmaceutical and dietary health care industry.

IPSCIO Record ID: 26256

License Grant
The Company entered into a license agreement with University that grants the Company an exclusive, worldwide license to (1) the PharmaPrint Process; (2) use certain therapeutic compounds; and (3) other related products developed by Dr. Khwaja's laboratory at USC. USC has also agreed to grant the Company the right to sublicense certain products and a right of first refusal to obtain a license for any improvements to certain products developed by USC. The term of the USC License Agreement began March 1, 1995, and ends on the later of February 28, 2010, or the expiration of the last issued patent under the USC License Agreement.
License Property
PharmaPrint Process technology develops pharmaceutical-grade dietary supplement products and pharmaceuticals from botanical sources. Unlike the traditional drug development process of identifying and synthesizing single bioactive molecules from plant sources, the Company's core technologies were developed based on empirical data that suggests that the health benefits and safe usage of certain plant-derived therapeutics might be the result of the natural combination of multiple molecules found in the plant extract and that single molecules, in isolation, may not replicate the natural plants' effectiveness. The PharmaPrint Process technology enables the Company to identify and quantify the bioactives within plant sources that are believed to provide therapeutic benefits and produce dietary supplements and pharmaceuticals having consistent batch-to-batch quantities and ratios of these bioactives.

IPSCIO Record ID: 319808

License Grant
Licensor hereby grants to Licensee, a shareholder and a related party, an exclusive, royalty bearing license under the Licensed Patents and Licensed Know How to develop, make, manufacture, use, sell, and commercialize the Licensed Products within the Field in the Territory. However, Licensee’s right to manufacture under this Agreement (other than by sourcing Licensed Product from Licensor under the Supply Agreement) will be limited to the circumstances identified in the Supply Agreement specifically permitting manufacturing by Licensee. Licensor shall maintain the exclusive worldwide rights to sell its products for Human Prescription Medicines, Over-the-Counter (OTC) Human Medicines, Animal Health Care Products and otherwise outside of the Field.

Exclusive License Limitation In the event that Licensee fails to meet its Minimum Sales Commitment (as defined in and pursuant to the terms of the Supply Agreement) during the first two consecutive calendar years of Minimum Sales Commitments (or any year thereafter), Licensee may continue to maintain exclusivity by paying Licensor the difference between (a) the Royalty that would have otherwise been earned by Licensor if Licensee had met its Minimum Sales Commitment and (b) actual Royalties paid to Licensor. If Licensee fails to pay to Licensor such minimum amount within thirty (30) days following the expiration of such period, Licensor shall have the right to permanently convert this exclusive license to a non-exclusive license (and to cause the Supply Agreement to be non-exclusive) by providing written notice to Licensee within ninety (90) days following the expiration of such thirty (30) day period. However, Licensee’s foregoing right to buy out its Minimum Sales Commitment will not apply unless Licensee has been using commercially reasonable efforts to achieve the Minimum Sales Commitments. Also, if Licensee fails to meet its Minimum Sales Commitment for any two consecutive years (excluding the initial year), Licensor shall have the right to permanently convert the exclusive license to a non-exclusive license (and the Supply Agreement to be non-exclusive) by providing 30 days’ written notice to Licensee.

License Property
Licensed Products means any products made utilizing Licensor’s Electrical Techniques that are low concentration silver, gold, and other similar low-concentration metal products, and any other products that may be agreed upon in writing by Licensor and Licensee from time to time, which products are listed.

Licensed Product Low concentrations of metallic silver or gold in water, and other similar low-concentration metal products made utilizing Licensor’s Electrical Techniques.

Electrical Techniques means that process or processes which include(s) the communication of at least one electrically conductive electrode with a liquid and wherein at least one electrochemical process, which utilizes at least one electric power source, occurs involving the at least one electrode and the liquid, as described in the Licensed Patents and Licensed Know How.

Licensed Patents means those patents and patent applications and any continuations, continuations-in-part and divisions of any such patents and patent applications, any Patents issuing from any of the foregoing, any extensions or supplementary Patent certificated thereto, and all foreign counterparts thereof, in each case that are owned or controlled by Licensor or any of its controlled affiliates during the Term of this Agreement.

Certain Human Non-Pharmaceutical Products means any product for human use, internally or externally, that (a) is used by consumers and which is not a Human Prescription Medicine or OTC Human Medicine or medical device or which otherwise makes a claim to mitigate, treat, cure, or prevent any human disease or disorder subject to regulatory approval by the United States Food and Drug Administration (FDA) or another similar and analogous approval from national regulatory authority of a jurisdiction in the Territory (but excluding approvals that may be required by national regulatory authorities for purposes other than Human Prescription Medicine or OTC Human Medicine), or (b) may be agreed upon in writing by Licensor and Licensee from time to time, which products are listed in Appendix B as may be updated by mutual written agreement of the Parties from time to time, provided that such agreement will not be unreasonably withheld or delayed.

Licensed IP means, collectively, the Licensed Patents, Licensed Know How and Licensed Products, and all intellectual property rights therein.

Human Prescription Medicines means any prescribed substance to treat or palliate any human disease or disorder or to improve human duration or quality of life.

Licensor is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. CSN therapeutics are comprised of atoms of transition elements that when assembled in nanocrystalline form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These nanocatalytic activities drive, support, and maintain beneficial metabolic and energetic intercellular reactions within diseased, stressed, and damaged cells.

Field of Use
rMetxTM (ZnAg Immune Boost) is an aqueous zinc-silver ion dietary (mineral) supplement made using our electrochemistry platform with bioactive immune-supporting properties.

Field means the research and development, use and commercialization of Nutritional Supplements and Certain Human Non-Pharmaceutical Products, for human use, internally or externally, which contain metallic-based constituent(s) that are formed by Electrical Techniques.

Nutritional Supplements means any food product, and any dietary supplement or food supplement product intended to supplement the human diet, that is not adulterated and is not a Human Prescription Medicine or an Over-the-Counter Medicine or a medical device or otherwise subject to regulatory efficacy approval by the FDA or another similar national regulatory authority of a jurisdiction in the Territory.

Licensee is an international supplier of health supplements.

IPSCIO Record ID: 173731

License Grant
Licensor grants the sole and exclusive right, without the right to grant sublicenses except to Licensees Affiliate(s), under the Patent Rights to market and sell Herbal Products, including the Licensed Products, in the OTC Market in the Territory.

Licensor grants a non-exclusive right, without the right to grant sublicenses except to Licensees Affiliate(s), under the Patent Rights to use the Herbal Products, including the Licensed Products, in the OTC Market in the Territory.

Licensor grants a non-exclusive license, without the right to grant sublicenses except to Licensees Affiliate(s), under the Trademark for use in conjunction with the marketing and/or sale of the Licensed Products in the OTC Market in the Territory, provided any such use of the Trademark shall be consistent with and recognize Licensors ownership thereof and reasonably comply with the standards of quality used and/or established by Licensor.

License Property
Licensor has developed a method for the identification, characterization of and regulation of the amounts of bioactive components in herbal products and is seeking to commercialize certain of the herbal  products identified, characterized and regulated thereby.  Licensor has developed technological know-how, obtained patents and filed patent applications.

The Trademark shall mean the trademark PHARMAPRINT.  Herbal Product shall mean a dietary supplement derived from botanical herbal extracts.

Field of Use
This agreement is for the dietary supplement industry.

IPSCIO Record ID: 271607

License Grant
The purpose of this Materials Transfer and Testing Agreement, is among other things, the research of original material made up of plants, plant matter, and plant extracts, the Plant Materials, to identify bioactive molecules contained in these Plant Materials which may lead to the commercial production of bioactive molecules.

The Licensee’s research and development efforts with Licensor, a non-profit institute,  have been centered on selective screening of certain natural product for the purpose of identifying extracts and further isolating molecules that may be effective as potential anti-inflammatory, neuro-protective and oxidative stress relieving molecules.

License Property
To date, the Licensee has screened one plant source and has fractionated extracts to determine its neuroprotective activity.  This plant source and extracted material has shown a high degree of neuroprotectant factor in the face of ethanol and ammonium toxicity in neuronal cell cultures.  Research activity has led to the discovery of novel molecules with biological activity and to the formation of new life sciences companies that will seek to commercialize discoveries centered on natural products.
Field of Use
The field of use is to develop methods and use of this material in the treatment of neurodegenerative diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.